
|Videos|November 30, 2017
Choosing Between TAS-102 and Regorafenib in Colorectal Cancer
Author(s)Cathy Eng, MD, FACP
Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses choosing between TAS-102 (Lonsurf) and regorafenib (Stivarga) in colorectal cancer.





































